SCHEMBL20325547

SCHEMBL20325547

CCOC(=O)C(F)(F)c1ccc(Cl)c(OC(C)C)c1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 4/20 0.44
MAPT P10636 4/20 0.44
MAPK1 P28482 1/20 0.44
LMNA P02545 3/20 0.41
ACSS2 Q9NR19 1/20 0.40
CCR1 P32246 1/20 0.39
CNR2 P34972 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
FBP1 P09467 1/20 0.38
TSHR P16473 2/20 0.38
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.37
PPARG P37231 1/20 0.37
RORC P51449 1/20 0.36
MRGPRX4 Q96LA9 1/20 0.36
P2RX3 P56373 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17420479 0.90 RORC (0.45) NPSR1MAPTMAPK1LMNAACSS2
SCHEMBL17420539 0.85 P2RX3 (0.43) MAPTMAPK1LMNAACSS2TSHR
SCHEMBL21501283 0.85 CNR2 (0.49) NPSR1MAPTMAPK1LMNAACSS2
SCHEMBL17420641 0.83 TSHR (0.41) MAPTMAPK1ACSS2TSHRALDH1A1
SCHEMBL30730313 0.82 MAPT (0.53) NPSR1MAPTMAPK1LMNAACSS2
SCHEMBL21501317 0.81 RORC (0.40) NPSR1MAPTLMNACCR1MEN1
SCHEMBL30313017 0.80 CNR2 (0.47) NPSR1MAPTMAPK1LMNAACSS2
SCHEMBL17420497 0.80 MAPT (0.46) NPSR1MAPTMAPK1LMNAACSS2
SCHEMBL30628213 0.80 MAPT (0.46) NPSR1MAPTMAPK1LMNAACSS2
SCHEMBL21501318 0.79 MAPT (0.40) NPSR1MAPTMAPK1LMNAACSS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190322676-A1 CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARM INC (US) 2019-10-24 US disclosed
WO-2018118838-A1 CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2018-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190322676-A1 CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE UGCG, MAN2B1, GBA1 NPSR1 4656/4885MAPT 308/4885MAPK1 2739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.